Ahpra registration PHY0002298174
How these guides are written and reviewed →
Chronic bronchitis means long-term inflammation of the airways with a cough that brings up phlegm on most days for months at a time. It is usually caused by smoking and is one of the two main parts of COPD (the other being emphysema). The airways make too much mucus and become narrowed, causing cough, phlegm and breathlessness. Stopping smoking, inhalers, and airway-clearance physiotherapy all help. This page explains chronic bronchitis and how we manage the mucus and breathlessness.
Definition
Chronic bronchitis is defined clinically, not by imaging or a blood test: a productive cough on most days for at least three months in each of two consecutive years, once other causes are excluded. It sits within the COPD spectrum and frequently coexists with emphysema — most people have elements of both. Importantly, chronic bronchitis can exist without airflow obstruction on spirometry, and that group still carries increased risk of exacerbations, faster lung function decline and progression to COPD.1
Pathophysiology
Mucus hypersecretion
Chronic exposure to irritants inflames the bronchial mucosa. Submucosal mucus glands enlarge and goblet cells multiply and extend further down the airway tree than normal, so more mucus is produced and it is produced in smaller airways that were never designed to carry it.
Impaired clearance
The same exposure damages and shortens cilia and alters mucus rheology, making it thicker and more adherent. Production rises while clearance falls — and coughing becomes the only remaining mechanism, which is why the cough is not incidental but compensatory. Suppressing it is unhelpful.
Small airway disease and the vicious cycle
Mucus plugging, inflammation and peribronchial fibrosis narrow and eventually obliterate small airways, producing fixed airflow obstruction. Retained secretions favour bacterial colonisation, colonisation drives further inflammation, and each infective exacerbation accelerates decline — a self-reinforcing cycle shared with bronchiectasis, and the reason airway clearance and exacerbation prevention matter so much.
Co-morbidities
As with COPD generally, common co-morbidities include cardiovascular disease, lung cancer, osteoporosis, sarcopenia and muscle wasting, anxiety and depression, gastro-oesophageal reflux, obstructive sleep apnoea and bronchiectasis overlap. Chronic mucus hypersecretion specifically identifies a phenotype with more frequent exacerbations, worse quality of life and greater healthcare use than COPD without it, so it is worth recording as a distinct feature rather than folding into a COPD label.
Prevalence
Chronic bronchitis is one of the two main components of COPD, which affects roughly one in thirteen Australians over 40. Chronic mucus production is reported by a substantial proportion of current smokers and by a meaningful minority of ex-smokers and never-smokers with occupational exposure. It is markedly under-reported: patients frequently regard a daily morning cough as normal for a smoker and do not mention it unless asked directly.
Causes and risk factors
- Tobacco smoking — the dominant cause in Australia, with a clear dose relationship.
- Occupational dusts, vapours, gases and fumes — mining, construction, welding, agriculture and cleaning products; a substantial and under-recognised contributor.
- Biomass smoke and air pollution, including indoor wood heating.
- Recurrent childhood and adult respiratory infection, which impairs airway development and clearance.
- Vaping — an emerging cause of chronic cough and sputum production, with long-term effects not yet established.
- Asthma–COPD overlap and untreated asthma, which can produce chronic mucus hypersecretion.
Symptoms
Typical features
- A persistent cough productive of clear, white, yellow or green sputum, typically worst on waking.
- Breathlessness on exertion, and wheeze or chest tightness.
- Frequent chest infections and flare-ups, often several each winter.
- Fatigue, disturbed sleep and reduced exercise tolerance.
Recognising an exacerbation
An exacerbation is a sustained worsening beyond normal day-to-day variation: more sputum, a change in its colour or thickness, more breathlessness, more wheeze, or a combination. Recognising the person’s own baseline is essential — green sputum in someone who always produces green sputum is not an exacerbation, and a small increase in volume in someone usually dry may be.
Warning signs
Diagnosis
Why diagnosis matters
Recognising chronic bronchitis prompts the interventions that matter most — smoking cessation, airway clearance and pulmonary rehabilitation — and identifies people at higher exacerbation risk who benefit from a written action plan. It also separates them from patients whose cough has another cause entirely.2,3
How is it diagnosed?
The diagnosis is made on the cough-and-sputum definition above, after excluding alternatives. Post-bronchodilator spirometry is essential to determine whether airflow obstruction coexists, since this changes both prognosis and treatment. Where spirometry is normal, the diagnosis is chronic bronchitis without obstruction — a real entity requiring follow-up, not a normal result.
Radiology
Chest X-ray is used to exclude other causes rather than to confirm the diagnosis. High-resolution CT is indicated where sputum volume is large, infections are recurrent, or haemoptysis occurs, principally to identify bronchiectasis — which is frequently present and changes management substantially.
Sputum and microbiology
Sputum culture guides antibiotic choice in frequent exacerbators and identifies chronic colonisation with organisms such as Pseudomonas aeruginosa, which carries prognostic weight. Mycobacterial culture is worth sending where there is weight loss, haemoptysis or a poor response to standard treatment.
Investigations for related conditions
An alpha-1 antitrypsin level is measured at least once. Assessment includes screening for cardiovascular disease, consideration of low-dose CT lung-cancer screening in eligible patients, and evaluation for reflux, sleep apnoea and asthma overlap. Where the cough is disproportionate to the exposure history, upper airway cough syndrome and ACE-inhibitor cough are considered.
Management
Management and goals
The goals are to stop progression, reduce sputum burden and cough, prevent exacerbations, maintain exercise capacity and function, and give the person the tools to manage flare-ups early themselves. Cure is not one of them, and being direct about that shifts the conversation productively towards what actually changes the trajectory.
Smoking cessation
The single most effective intervention. In the Lung Health Study, a smoking cessation programme in smokers with mild to moderate airflow obstruction significantly reduced the age-related decline in FEV1 over five years compared with usual care, and sustained quitters showed the greatest benefit.4 Cough and sputum improve within weeks to months of stopping — a tangible, near-term reward worth naming, since abstract talk of decline rates rarely motivates. Cessation support combines pharmacotherapy with behavioural support.
Airway clearance
A daily clearance routine is central where sputum is a daily problem. A Cochrane review found airway clearance techniques in COPD reduced the need for ventilatory assistance and shortened hospital stay, with improvements in health-related quality of life, though without changing mortality or lung function.5 Technique choice is individual and adherence matters more than which method is chosen.
Pulmonary rehabilitation
Pulmonary rehabilitation produces clinically significant improvements in breathlessness, fatigue, emotional function and sense of control in COPD, with effect sizes larger than most drug treatments.6 Delivered after an exacerbation it reduces hospital readmissions and mortality and improves quality of life — making the post-exacerbation window one of the highest-value referral points in respiratory care.7
Inhaled therapy and vaccination
Long-acting bronchodilators (LAMA and/or LABA) ease breathlessness and reduce exacerbations where obstruction is present, with inhaled corticosteroids added in exacerbation-prone, eosinophilic patients. Vaccination against influenza, pneumococcus, COVID-19 and RSV is part of standard care and is checked at every review.
Action plan and self-management
A written action plan setting out the person’s baseline, what a flare-up looks like for them, when to start rescue medication and when to seek help reduces the severity and duration of exacerbations. See recognising a flare-up.
Identifying deterioration
Increasing exacerbation frequency, new haemoptysis, weight loss, worsening exercise tolerance despite treatment, or persistent purulent sputum all warrant reassessment — for bronchiectasis, bacterial colonisation, malignancy, mycobacterial infection or cardiac disease.
Medications
Medications for chronic bronchitis
Inhaled therapy is central where obstruction coexists, and correct technique is the strongest determinant of benefit — it is checked at every visit, not assumed. Mucoactive agents, including nebulised saline, can aid clearance in selected patients.
Mucolytics
Oral mucolytics produce a small reduction in exacerbations and days of disability in chronic bronchitis and COPD, with the benefit greatest in those not on inhaled corticosteroids.8 High-dose N-acetylcysteine, 600 mg twice daily, significantly reduced exacerbation frequency in Chinese patients with moderate to severe COPD.9 The effect is modest but the treatment is cheap and well tolerated, making it a reasonable option in frequent exacerbators.
Preventing exacerbations pharmacologically
In severe COPD with chronic bronchitis and frequent exacerbations despite triple inhaled therapy, roflumilast further reduced moderate to severe exacerbations.10 Long-term azithromycin taken daily reduced exacerbation frequency and improved quality of life, at the cost of hearing decrement and increased macrolide resistance — so it is used selectively, with audiometry and ECG screening.11
Correct use of medications
Inhaler technique is reviewed at every appointment and after every device change, since a change of device without retraining reliably reduces effectiveness. Spacers are used with pressurised metered dose inhalers. Antibiotics are reserved for exacerbations with increased sputum purulence and volume rather than given for every increase in cough.
Multi-system manifestations
Cardiovascular
Ischaemic heart disease, heart failure and arrhythmia are markedly more common and are a leading cause of death in this population — driven by shared smoking exposure, systemic inflammation and hypoxaemia. Breathlessness attributed to the lungs is frequently partly cardiac.
Skeletal muscle
Peripheral muscle wasting and weakness, particularly of the quadriceps, occurs independently of lung function and is a stronger predictor of exercise capacity and mortality than FEV1. It is directly modifiable with exercise training, which is the argument for rehabilitation over reassurance.
Bone
Osteoporosis is common, driven by smoking, inactivity, low body weight, systemic inflammation and corticosteroid exposure. Vertebral fracture worsens respiratory mechanics, creating a loop worth interrupting with bone density assessment and weight-bearing exercise.
Mood and cognition
Anxiety and depression affect a large minority and are independently associated with more exacerbations, poorer adherence and worse quality of life. Breathlessness-related panic is a specific and treatable problem.
Nutrition and body composition
Both low body weight with muscle loss, and obesity with deconditioning, worsen outcomes. Body composition matters more than weight alone, and unintentional weight loss is a poor prognostic sign requiring dietetic input.
Sleep
Nocturnal cough, hypoxaemia and coexisting obstructive sleep apnoea (overlap syndrome) fragment sleep and worsen daytime symptoms, pulmonary artery pressures and cardiovascular risk.
Living with chronic bronchitis
A daily clearance routine
The routine that gets done is the one that fits the day. Most people settle on clearance after waking and before bed, timed around bronchodilators, taking ten to fifteen minutes. Building it into an existing habit works better than scheduling it separately.
Staying active
Activity is treatment, not merely advice. Breathlessness on exertion is not harmful, and avoiding it produces the deconditioning that makes it worse — a cycle worth naming explicitly, since most people have been quietly reducing what they do for years.
Nutrition
Adequate protein supports muscle mass, and smaller more frequent meals reduce the breathlessness that comes with a full stomach pressing on a flattened diaphragm. Weight loss is investigated rather than welcomed.
Sleep and mood
Nocturnal cough and anxiety both disturb sleep, and poor sleep amplifies breathlessness and fatigue the following day. Both are asked about directly and treated.
Avoiding irritants
Beyond tobacco: wood heaters, aerosol cleaning products, workplace dust and fumes, and bushfire smoke. Practical mitigation — ventilation, respiratory protection at work, checking air quality on smoke days — is more useful than blanket avoidance advice.
Travel and vaccination
Most people travel without difficulty, with an in-flight oxygen assessment where lung function is significantly impaired. Vaccinations are kept current, and a supply of rescue medication and a copy of the action plan travel with them.
Prognosis
The outlook depends on whether airflow obstruction is present, exacerbation frequency, exercise capacity and, above all, smoking status. Chronic mucus hypersecretion independently predicts more frequent exacerbations, faster FEV1 decline and higher hospitalisation risk. The trajectory is genuinely modifiable: in long-term follow-up of the Lung Health Study, participants randomised to a smoking cessation intervention had significantly lower all-cause mortality at 14.5 years than those receiving usual care.12 Airway clearance and pulmonary rehabilitation meaningfully reduce symptoms and exacerbations and improve quality of life, even where lung function does not change.
Role of the physiotherapist
Physiotherapy targets the two problems that most limit these patients — mucus and breathlessness — and does so more directly than any drug. Airway clearance is prescribed and reviewed individually: the active cycle of breathing technique, autogenic drainage, an oscillating PEP device, or nebulised saline as an adjunct, with gravity-assisted positioning where appropriate. Technique is taught, then reviewed, then reviewed again — the common failure is not choosing the wrong technique but assuming it is still being done correctly a year later.
Pulmonary rehabilitation is the intervention with the strongest evidence base in this population, and physiotherapists deliver it: exercise prescription, progression, breathlessness management and the education that makes self-management possible. Referral after an exacerbation is particularly high value.
Alongside these: breathing retraining and pacing for breathlessness and panic, energy conservation, inhaler technique review at every contact, support with the written action plan, and early recognition of the exacerbation trajectory that needs medical escalation. Physiotherapists frequently have more contact time than any other clinician with these patients, which makes them well placed to notice weight loss, rising exacerbation frequency or new haemoptysis and to act on it.
Part 1 · References
- Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(3):228–237.
- Yang IA, George J, McDonald CF, et al. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.78. Brisbane: Lung Foundation Australia and Thoracic Society of Australia and New Zealand; October 2025. Available at: copdx.org.au
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD: 2026 report. GOLD; 2026. Available at: goldcopd.org
- Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272(19):1497–1505.
- Osadnik CR, McDonald CF, Jones AP, Holland AE. Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(3):CD008328.
- McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;(2):CD003793.
- Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016;(12):CD005305.
- Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2019;(5):CD001287.
- Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014;2(3):187–194.
- Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385(9971):857–866.
- Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689–698.
- Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233–239.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
More than one of our services applies here, and which combination suits you depends on what your assessment shows.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. Chronic bronchitis is a symptom-defined phenotype — productive cough on most days for three months in two consecutive years — that may exist with or without airflow obstruction. Where it coexists with COPD it independently predicts more frequent exacerbations, faster lung-function decline, worse quality of life and higher mortality, which is why it is worth identifying as a phenotype rather than folding into a global COPD label.1,2,3
What alters the trajectory
- Smoking cessation remains the only intervention shown to change the rate of FEV1 decline, and the Lung Health Study cohort showed a mortality benefit sustained at 14.5 years. Cough and sputum frequently improve within months of quitting.4,5
- Airway clearance techniques in COPD reduce the need for ventilatory assistance and shorten hospital stay during exacerbations, with small quality-of-life gains, but do not improve lung function or mortality — they are targeted therapy for sputum burden, not routine care for every patient.6
- Mucolytics (carbocisteine, N-acetylcysteine) produce a modest reduction in exacerbations and days of disability, with a stronger signal at higher doses in the PANTHEON trial.7,8
- Pulmonary rehabilitation delivers the largest and most reliable improvements in dyspnoea, exercise capacity and quality of life; started after an exacerbation it reduces readmission and improves quality of life, with the greatest effect when begun within weeks rather than months.9,10
- Phenotype-directed pharmacotherapy matters here: roflumilast reduces exacerbations specifically in chronic bronchitis with severe obstruction and a frequent-exacerbator pattern, and long-term azithromycin reduces exacerbation frequency in selected patients.11,12
Physiotherapy implications
- Select for clearance, do not default to it. Prescribe airway clearance where sputum volume, difficulty expectorating or exacerbation-related retention is demonstrable; oscillating PEP and ACBT are the usual choices, taught and then reviewed in practice.6
- Teach the huff, not the cough. In airflow obstruction a forced cough drives dynamic airway collapse; huffing at mid to low lung volumes with a stable breathing pattern is more productive and less exhausting.
- Optimise inhaled therapy around the routine: reliever before clearance, and inhaled corticosteroid-containing maintenance therapy afterwards, so it deposits on cleared airways — then check technique, which is wrong more often than not.
- Treat smoking cessation as a physiotherapy task: brief advice at every episode of care plus active referral to Quitline or pharmacotherapy is the single highest-yield action in the session.4,5
- Screen for cough-related urinary incontinence and for the breathlessness–inactivity–deconditioning spiral; both change adherence and neither is usually volunteered.
- Capture the post-exacerbation window — enrolment into rehabilitation shortly after discharge is more effective than a place on a waiting list months later.10
Clinical reasoning
- Distinguish chronic bronchitis with normal spirometry from COPD with the chronic bronchitis phenotype: the former needs cough, smoking and irritant management, the latter the full COPD-X package.1
- Daily purulent sputum in large volumes, recurrent infections or haemoptysis should raise bronchiectasis and prompt HRCT rather than more intensive clearance.
- A change in cough character, new haemoptysis or unexplained weight loss in a smoker is a red flag for malignancy, not a physiotherapy problem.
- Exercise intolerance out of proportion to spirometry warrants a look at cardiac disease, deconditioning, anaemia and breathing pattern disorder before intensifying respiratory treatment.
Evidence gaps
- Trials rarely separate the chronic bronchitis phenotype from COPD generally, so technique- and dose-specific evidence for this group is thin.
- Optimal frequency and duration of maintenance airway clearance outside exacerbations is undefined.
- Whether mucolytics add benefit on top of an established clearance routine has not been tested directly.
- Little evidence guides management of chronic bronchitis with preserved spirometry, despite its recognised symptom burden.
References for the clinical evidence summary
- Yang IA, George J, McDonald CF, et al. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.78. Brisbane: Lung Foundation Australia and Thoracic Society of Australia and New Zealand; October 2025. Available at: copdx.org.au
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD: 2026 report. GOLD; 2026. Available at: goldcopd.org
- Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(3):228–237.
- Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994;272(19):1497–1505.
- Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233–239.
- Osadnik CR, McDonald CF, Jones AP, Holland AE. Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(3):CD008328.
- Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2019;(5):CD001287.
- Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014;2(3):187–194.
- McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;(2):CD003793.
- Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016;(12):CD005305.
- Martinez FJ, Calverley PMA, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385(9971):857–866.
- Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689–698.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.